Cargando…
Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
INTRODUCTION: Prospective data about quality of life (QoL) in men with breast cancer (BC) are lacking. A prospective registry (EORTC10085) of men with all BC stages, including a QoL correlative study, was performed as part of the International Male Breast Cancer Program. METHODS: Questionnaires at B...
Autores principales: | Schröder, Carolien P, van Leeuwen-Stok, Elise, Cardoso, Fatima, Linderholm, Barbro, Poncet, Coralie, Wolff, Antonio C, Bjelic-Radisic, Vesna, Werutsky, Gustavo, Abreu, Miguel H, Bozovic-Spasojevic, Ivana, den Hoed, Irma, Honkoop, Aafke H, Los, Maartje, Leone, Jose P, Russell, Nicola S, Smilde, Tineke J, van der Velden, Annette W G, Van Poznak, Catherine, Vleugel, Marije M, Yung, Rachel L, Coens, Corneel, Giordano, Sharon H, Ruddy, Kathryn J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546813/ https://www.ncbi.nlm.nih.gov/pubmed/37310797 http://dx.doi.org/10.1093/oncolo/oyad152 |
Ejemplares similares
-
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases
por: Anders, Carey, et al.
Publicado: (2014) -
CXCR3 antagonist VUF10085 binds to an intrahelical site distinct from that of the broad spectrum antagonist TAK–779
por: Nedjai, Belinda, et al.
Publicado: (2015) -
FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036
por: Angus, Steven P., et al.
Publicado: (2021) -
TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
por: Freedman, Rachel A., et al.
Publicado: (2019) -
Elastosis in ERα-positive male breast cancer
por: Vermeulen, Marijn A., et al.
Publicado: (2020)